Tweets
@DiegoBenavent et al: Gender impacts disease outcomes in PsA and SpA. Women > BASDAI, >BASFI, > ASDAS, >ASDAS Hi, and > EQ-5D.
Not so surprising considering higher ratio for Fibromyalgia in W
ASDAS not asso w/ gender in AxSPA.
https://t.co/kBxvAi5qZw
Abstr #0381 #ACR22 @Rheumnow https://t.co/vxdtlKpT3l
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
We've never been convinced on adjunct therapy in GCA - yet we're still worried about aortic dilatation.
Beta-blockers we're def not doing - but impressive retrospective data here.
Let's test this properly!
ABST0477 #ACR22 @RheumNow
(also @seminarthrheum https://t.co/onKW2JKIzo) https://t.co/yHTx29NJNX
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
Black study subjects remain underrepresented in rheumatology clinical trials except for gout. Abs 0089
Continued under-reporting of race and ethnicity in PsA trials. Abs 0090
We can do better #rheumtwitter
#ACR22 @RheumNow https://t.co/lzFXxFxgNs and https://t.co/K9dYaaXCg8 https://t.co/VqQe1OCsKg
Links:
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Germany based 74 pt #FMF prospective non-interventional, multicenter observational study on Canakinumab - RELIANCE Registry
63% in remission in 2 yrs
serious adverse drug reactions - 1.56 per 100 patient years
@RheumNow #ACR22 abst#0138
Bella Mehta @bella_mehta ( View Tweet )
3 years 8 months ago
@ericdeinmd is moderating a great session, difficult to treat RA at #ACR22 right now! #rheumpix @RheumNow https://t.co/R5yg3eme6v
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/y7VWk3lOXD
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
Culerrier @AKronbichler @TerrierBen et al. AAV induced by anti-thyroid drugs. 45 cases. vs AAV - younger (45 vs 68) More skin (54 vs 25%) Less renal (38 vs 73%) Less severe (BVAS 9 vs 13) Less relapse (HR 0.07). Can rechallenge! @rheumnow #ACR22 Abstr#0436 https://t.co/0i7zj615N6 https://t.co/t7fWCOuUsJ
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
OPAL data is a gem! Large Australian data studying JAKi use in #rheumatoidarthritis N=5900 Switching JAKi~JAKi-common. As in TNFi 1st line Rx had longer retention & better efficacy than 2nd & subsequent. Median 1st advanced Rx - same in all JAKs 34 MOA @RheumNow #ACR22 abst0274 https://t.co/FQU4AKXwe9
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Dey @DrMiniDey @ElenaNikiUK @docrota @LatikaGupta_ et al. COVID vaccination in IIM+multimorbidity. Adverse events more common, but still infrequent. Both multimorbidity and active IIM increased risk of AEs. @rheumnow #ACR22 Abstr#0177 https://t.co/HA5NaRrPYL https://t.co/TKtagwa0gG
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Coming soon on #ACR22:
Stream session 12S119 on @ACRheum and @ACRheumDC advocacy
What is new on the Hill?
What are ACR priorities
How quickly can you send an email supporting rheumatologists (quicker than you think!)
@RheumNow
@AngusWorthing @BlairSolowM @LennMcD @LouisaZiglar https://t.co/sXSBGbCZyM
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Froehlich et al. MRI superior to US in GCA. For all GCA sensitivity 73% vs 45%. For supra-aortic GCA sensitivity 73% vs 59%. Both 100% specificity. @rheumnow #ACR22 Abstr#0493 https://t.co/vf2r0h5zUd https://t.co/mlSCcpy2uK
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Very complex conversation on why opioids are used...
Opioid use in patients with PsA and AS led to higher healthcare utilization and higher costs.
Opioid users - more co-morbidities, smokers, worse disease activity
Opioid users spent more on drug costs
Abs#0402 @RheumNow #ACR22 https://t.co/dbUPg5LGLy
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 8 months ago
